1. [A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy].
- Author
-
Otsuka S, Inagaki M, Nishie M, Hamano R, Tokunaga N, Takahashi K, Tsunemitsu Y, Miyoshi K, Iwakawa K, Takahashi M, and Iwagak H
- Subjects
- Adult, Aged, Antibodies, Monoclonal, Humanized, Bevacizumab, Colorectal Neoplasms surgery, Fluorouracil administration & dosage, Humans, Leucovorin administration & dosage, Liver Neoplasms surgery, Male, Organoplatinum Compounds administration & dosage, Angiogenesis Inhibitors administration & dosage, Antibodies, Monoclonal administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Colorectal Neoplasms pathology, Liver Neoplasms drug therapy, Liver Neoplasms secondary, Neoplasms, Second Primary drug therapy, Neoplasms, Second Primary secondary
- Abstract
A 25-year-old man with RS rectal cancer received a radical resection of the original tumor and lymph node dissection. Oral tegafur/uracil (UFT)/Leucovorin (LV) therapy has been used for adjuvant chemotherapy, as the pathological Stage was T3N1M0, Stage IIIa. After 10 months from operation, multiple liver metastases were recognized and not resectable. So a systemic chemotherapy by mFOLFOX6+bevacizumab was begun via CV port. After 5 courses of mFOLFOX6+bevacizumab, abdominal CT revealed liver metastases showed remarkable reduction in size. Hepatic resection of S6 segment was enforced, and the patient uneventfully discharged. Pathological findings of S6 segment revealed no residual cancer cells, indicating the histological effect of mFOLFOX6+bevacizumab was Grade 3. And no liver damage was recognized.
- Published
- 2009